AR and breast carcinoma: Indeed, a phase II trial of bicalutamide, an androgen antagonist, in patients with metastatic AR+ER− breast cancer, the 6-month clinical benefit rate was 19% for bicalutamide, which established the potential of targeting AR in ER- disease [23].